RxDoctor Payments Data

Lindsay Rhinevault, NP

Acute Care · Rochester, NYNPI 1760191407

Payments from drug & device makers

$1,709in general payments, 2019–2025

Across 63 payments — averaging $27.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$360
  • Novartis$316
  • Amgen$179
  • Agepha Pharma FZ LLC$156
  • E.r. Squibb & Sons, L.L.C.$138
  • Boehringer Ingelheim$116
  • plus $446 from 10 others

What the payments were for

  • Food & beverage$1,709100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,709 in reported general payments places this provider in the 85th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Medicare billing

Part B allowed, 2024
$12,417
Medicare patients
142
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban265$319,944
EntrestoSacubitril/Valsartan97$106,196
FarxigaDapagliflozin Propanediol59$56,028
JardianceEmpagliflozin31$44,839
BrilintaTicagrelor27$30,607
Repatha SureclickEvolocumab38$29,580
Praluent PenAlirocumab25$20,369
XareltoRivaroxaban11$15,824
VascepaIcosapent Ethyl12$11,037
Icosapent Ethyl26$8,088
Metoprolol Succinate309$6,482
Atorvastatin Calcium370$6,217
Ezetimibe122$4,686
Rosuvastatin Calcium179$3,731
ClopidogrelClopidogrel Bisulfate160$2,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$319,944265 claims
NovartisEntresto$316$106,19697 claims
AstraZenecaFarxiga, Brilinta$360$86,63586 claims
Boehringer IngelheimJardiance$116$44,83931 claims
Johnson & JohnsonXarelto$45$15,82411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 980 acute care providers in New York.

Other acute care in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →